Percepta Genomic Sequencing Classifier and decision-making in patients with high-risk lung nodules: a decision impact study.

ABSTRACT:

Background

Incidental and screening-identified lung nodules are common, and a bronchoscopic evaluation is frequently nondiagnostic. The Percepta Genomic Sequencing Classifier (GSC) is a genomic classifier developed in current and former smokers which can be used for further risk stratification in these patients. Percepta GSC has the capability of up-classifying patients with a pre-bronchoscopy risk that is high (> 60%) to "very high risk" with a positive predictive value of 91.5%. This prospective, randomized decision impact survey was designed to test the hypothesis that an up-classification of risk of malignancy from high to very high will increase the rate of referral for surgical or ablative therapy without additional intervening procedures while increasing physician confidence

SUBMITTER: Sethi S 

PROVIDER: S-EPMC8740045 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature